This candidate will be a member of the Ipilimumab Global Marketing team. Major responsibilities will include - Leadership of the prostate cancer program oPositioning work o Label Optimization (Collaboration with the clinical, medical and regulatory team to ensure commercial success) o Patient Insight work o Tumor Strategy Group Member (Opportunity to provide input to franchise strategy: Future market Map, Scenario Planning, CI readiness) Leadership of the pancreatic program o Label Optimization (Collaboration with the clinical, medical and regulatory team to ensure commercial success) o Preparation for key DP discussions o Choices 1-5 o Collaboration with franchise GI tumor lead Management of innovative virtual insight exchange program for all indications Key commercial member to the future tumor planning for the brand o Lead commercial tumor deep dives for assessment of attractiveness Management of the Competitive Intelligence Plan for non-Melanoma indications Collaboration with advertising agency, medical education agency and interactive agency to drive performance of projects Collaboration with SPDA on Forecasting for LCM opportunities. This position will work closely with the melanoma team to insure integration of learnings is rapidly applied and appropriate market development is being identified.
2 plus years of Global Marketing and operational Marketing experience at the D7 level. MBA or equivalent. Understanding of the oncology marketplace and demonstrated ability to learn about different tumor types (preferable). Experience in communication and leadership of teams across various functions. Ability and desire to analyze clinical data. Strong interpersonal skills and ability to motivate and build alignment across matrix teams. Demonstrated ability to effectively and efficiently drive performance within a matrix organization. Analytical thinking and innovative approach to problem solving. Experience in strategic thinking and executing against plans. Ability to demonstrate expertise in marketing analytics and market, customer & competitive insight
Job Function: Marketing
Primary Location: NA-US-NJ-Princeton
It is not about the patient, it is about how they can leverage this drug in the marketplace
The results were so startling that researchers decided to release details of the two cases before the drug trial – in which the patients took part – was complete. Doctors said their progress had exceeded all expectations. The men were treated at the Mayo Clinic in Minnesota in the US, one of the top medical centres in the world.
Dr Eugene Kwon, the urologist who was in charge of their treatment, compared the results to the first pilot breaking the sound barrier.
"This is one of the Holy Grails of prostate cancer research. We have been looking for this for years," he said.
Ipilimumab is one of a class of drugs called monoclonal antibodies, which stimulate the body's own immune system to fight disease. The experimental treatment is being developed by Bristol-Myers Squibb and Medarex, a US biotech company. The drug is being trialled on malignant melanoma, the most serious form of skin cancer, Hodgkin's disease, lung cancer and prostate cancer. Studies are most advanced in melanoma, where it has been shown to prolong survival in patients with advanced forms of the disease. In the Mayo Clinic study of prostate cancer, researchers say that standard hormone treatment ignited the immune response, and adding ipilimumab was like "pouring gasoline on the pilot light".